NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Absci Corporation (ABSI) Stock Analysis

Absci Corporation (ABSI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABSI

$8.82

+$0.02 (+0.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABSI with… →

ABSI Key Statistics

As of Sep 4, 2026
Trading
Open
$8.69
Previous Close
$8.80
Day's Range
8.65–9.03
52-Week Range
2.24–12.06
Volume
2.13M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.44
Valuation
Market Cap
$1.51B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
969.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.79
Financials (FY)
Revenue (FY)
$2.80M−38.24%
Net Income (FY)
−$115.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
171.61M
1-Year Return
+267.50%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
4.69M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABSI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+152.72%
2025+33.21%
2024−37.62%
2023+100.00%
2022−74.39%
2021 (partial year)−62.02%

As of September 4, 2026.

ABSI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.80M−$115.18M−4113.7%
2024$4.53M−$103.11M−2274.1%
2023$5.72M−$110.57M−1933.6%
2022$5.75M−$104.90M−1825.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.80M—−$125.42M−$115.18M−4113.7%
2024$4.53M—−$108.89M−$103.11M−2274.1%
2023$5.72M—−$94.18M−$110.57M−1933.6%
2022$5.75M—−$106.75M−$104.90M−1825.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABSI Valuation vs Biotechnology Median

Median of 656 stocks
MetricABSIBiotechnology medianvs median
P/S ratio969.6615.2663.5x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Absci Corporation (ABSI) at $1.51B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 140 employees.

ABSI last closed at $8.82 on September 4, 2026. That is +$0.02 (+0.23%) against the previous close. The 52-week range on file runs from $2.24 to $12.06. The latest close sits 293.75% above that 52-week low.

Financial Health

In fiscal 2025, Absci Corporation reported revenue of $2.80M. That is −38.24% against the prior fiscal year, when revenue was $4.53M. The same year closed with a net loss of $115.18M. Profit margin runs at 0%. Trailing earnings per share are −0.79.

Across the 4 fiscal years on file, revenue moves from $5.75M in 2022 to $2.80M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 969.66 times revenue. On price-to-sales that is 63.5 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +267.50%. Measured over 5 years, that is −15.17% a year compounded. Beta against the wider market is reported at 2.44. Annualized volatility over the trailing 5 years is 97.32%.

Growth & Income

No dividend is on file for ABSI.

So far in 2026 the price is +152.72%. Across the complete calendar years on file, 2023 returned +100.00% and 2022 returned −74.39%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Absci Corporation (ABSI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Absci Corporation ABSI $1.51B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Absci Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Absci Corporation

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Visit website →